Online citations, reference lists, and bibliographies.
← Back to Search

Bronchial Aspirin Challenge Causes Specific Eicosanoid Response In Aspirin-sensitive Asthmatics.

A. Szczeklik, K. Sladek, R. Dworski, E. Nizankowska, J. Soja, J. Sheller, J. Oates
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
We have shown that inhalation of lysine aspirin enhances leukotriene production in the lungs of patients with aspirin-induced asthma (AIA). To assess the specificity of this reaction, we compared two well-matched groups of patients: eleven with AIA versus 14 asthmatics tolerant to aspirin (ATA). All subjects underwent bronchoalveolar lavage (BAL) with saline followed immediately by instillation of 10 mg of lysine aspirin, into a right middle lobe segmental bronchus, which was lavaged 15 min later. At baseline the two groups did not differ with respect to BAL fluid concentrations of cyclooxygenase products, peptido-leukotrienes, histamine, tryptase, interleukin-5 (IL-5), eosinophil cationic protein (ECP), or eosinophil number. Fifteen minutes after aspirin instillation, there was a statistically significant rise in peptido-leukotrienes, IL-5, and eosinophil number in AIA, but not in ATA, but not in ATA patients. In the former, but not in the latter group, mean histamine concentrations rose in response to aspirin, approaching the level of statistical significance. Tryptase and ECP levels showed no significant change. Aspirin significantly depressed PGE2 and thromboxane B2 (TXB2) in both groups, however PGD2, PGF2 alpha, and 9 alpha, 11 beta-PGF2 decreased only in ATA patients. A characteristic disturbance in eicosanoid balance, produced by aspirin in patients intolerant to this drug, might explain precipitation of asthma attacks.
This paper references
10.1136/bmj.1.5949.67
Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients.
A. Szczeklik (1975)
10.1016/0006-2952(84)90362-9
Interactions between prostaglandins and leukotrienes.
F. A. Kuehl (1984)
10.1016/0091-6749(76)90102-0
[Aspirin-induced asthma].
A. Szczeklik (1986)
10.1164/AJRCCM/137.4.847
Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin.
N. Ferreri (1988)
10.1111/j.1365-2222.1988.tb02838.x
Aspirin‐induced asthma as a viral disease
A. Szczeklik (1988)
10.1164/AJRCCM/139.1.46
Allergen-stimulated release of mediators into sheep bronchoalveolar lavage fluid. Effect of cyclooxygenase inhibition.
R. Dworski (1989)
The cyclooxygenase theory of aspirin-induced asthma.
A. Szczeklik (1990)
10.1164/AJRCCM/143.5_PT_1.1025
Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects.
P. Christie (1991)
10.1164/AJRCCM/144.4.957
The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.
P. Christie (1991)
10.1164/AJRCCM/145.1.65
Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients.
C. Picado (1992)
10.1164/AJRCCM/145.2_PT_2.S34
Mechanism of aspirin sensitivity.
T. Lee (1992)
10.1164/AJRCCM/146.1.96
Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.
M. Kumlin (1992)
Prostaglandin E2 limits arachidonic acid availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages by a nonphospholipase A2 mechanism.
B. Christman (1993)
Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.
K. Sladek (1993)
The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.
B. Dahlén (1993)
10.1016/0140-6736(93)91073-U
Leukotriene E4 and granulocytic infiltration into asthmatic airways
L. Laitinen (1993)
10.1016/0091-6749(94)90123-6
Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
A. Fischer (1994)
10.1016/s0021-9258(17)36820-5
Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin.
M. Lecomte (1994)
10.1164/AJRCCM.149.4.8143059
Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.
K. Sladek (1994)
10.1038/NSB0895-637
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
P. Loll (1995)
10.1038/NM0496-449
Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia
E. García-Zepeda (1996)
10.1164/AJRCCM.153.2.8564100
Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.
P. Sestini (1996)
10.1164/AJRCCM.153.1.8542168
Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects.
S. Nasser (1996)
10.1136/thx.51.1.64
Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects.
S. Nasser (1996)



This paper is referenced by
10.1016/B978-0-08-102723-3.00090-1
Mechanisms of Allergy
I. Agache (2021)
10.3389/fphar.2020.594427
Platelet-Adherent Leukocytes Associated With Cutaneous Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs
R. Jurado‐Escobar (2020)
10.3390/ijms21051851
The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy
Kijeong Lee (2020)
10.2147/JAA.S237463
The Role of Mast Cells in Aspirin-Exacerbated Respiratory Disease (AERD) Pathogenesis: Implications for Future Therapeutics
M. Kuruvilla (2020)
10.1016/j.jaci.2020.08.007
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.
B. Jakiela (2020)
10.5935/2318-5015.20190033
Mepolizumabe na doença respiratória exacerbada por aspirina - DREA
M. Lopes (2019)
10.1016/j.wjorl.2018.08.001
Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease
T. Laidlaw (2018)
10.1016/j.otc.2016.08.007
Aspirin-Exacerbated Respiratory Disease.
E. Walgama (2017)
10.1007/s11882-017-0673-6
Update on Aspirin-Exacerbated Respiratory Disease
K. Woessner (2017)
10.1172/JCI95717
Leukotrienes and sex: strange bedfellows?
L. J. Smith (2017)
10.1159/000444798
Allergic Reactions to Metamizole: Immediate and Delayed Responses
N. Blanca-Lopez (2016)
10.1038/emm.2015.96
Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease
Su-Kang Kong (2016)
10.1016/j.iac.2016.06.005
Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease.
Katherine N Cahill (2016)
10.1016/j.iac.2016.06.011
Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
Jennifer L. Hill (2016)
10.1016/j.trsl.2016.02.011
Emerging concepts: mast cell involvement in allergic diseases.
B. Modena (2016)
10.1016/J.ALERGO.2015.01.001
Mechanisms of aspirin hypersensitivity – What is known up to now
Weronika Łagan (2015)
10.1016/j.jaci.2014.07.031
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
K. Cahill (2015)
10.1016/j.prostaglandins.2015.07.001
Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
L. Mastalerz (2015)
10.1111/all.12512
Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity
L. Mastalerz (2014)
10.5414/ALX01584
In-vitro-Diagnostik des ASS-Intoleranz- Syndroms (Aspirin-exacerbated Respiratory Disease: AERD)
R. Dollner (2014)
Desensibilización al ácido acetil-salicílico como tratamiento para la enfermedad respiratoria exacerbada por antiinflamatorios no esteroides
Ricardo Cardona Villa (2014)
10.1016/j.pupt.2013.10.001
Plasma apolipoprotein H levels are different between aspirin induced respiratory diseases and aspirin tolerant asthma.
H. Kim (2014)
10.4049/jimmunol.1301753
Aspirin Activation of Eosinophils and Mast Cells: Implications in the Pathogenesis of Aspirin-Exacerbated Respiratory Disease
J. Steinke (2014)
Prostaglandin D 2 : A dominant mediator of aspirin-exacerbated respiratory disease
K. Cahill (2014)
Desensitization to acetyl-salicylic acid as a treatment for non-steroid anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease
Ricardo Cardona Villa (2014)
10.1111/cea.12371
Systems biology approaches to enhance our understanding of drug hypersensitivity reactions
J. Perkins (2014)
10.1371/journal.pone.0090966
Variants of CEP68 Gene Are Associated with Acute Urticaria/Angioedema Induced by Multiple Non-Steroidal Anti-Inflammatory Drugs
J. A. Cornejo-García (2014)
New perspectives in monitoring lung inflammation
P. Montuschi (2014)
10.1159/000369827
Altered Inhibitory Function of the E-Type Prostanoid Receptor 4 in Eosinophils and Monocytes from Aspirin-Intolerant Patients
P. Luschnig (2014)
ASTHMA ( WJ CALHOUN AND SP PETERS , SECTION EDITORS ) Which Biomarkers Are Effective for Identifying Th 2-Driven Inflammation in Asthma ?
Z. Diamant (2013)
10.1016/j.iac.2012.11.003
Mechanisms of aspirin desensitization.
T. Burnett (2013)
10.2217/pgs.13.166
Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations.
J. A. Cornejo-García (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar